High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2014-01, Vol.49 (1), p.148-149
Hauptverfasser:	Nishihori, T, Hassoun, Y, Zhang, L, Shain, K, Alsina, M, Kharfan-Dabaja, M A
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/737 692/699/1541 692/699/67/1990/804 692/700/565/545/576/1855 Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow Bone Marrow - pathology Bone marrow, stem cells transplantation. Graft versus host reaction Cell Biology Dosage and administration Drug therapy Female Granulocyte Colony-Stimulating Factor - chemistry Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Humans Hydroxyurea - therapeutic use Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Internal Medicine Janus Kinase 2 - genetics letter-to-the-editor Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical research Medical sciences Medicine Medicine & Public Health Medicine, Experimental Melphalan Melphalan - administration & dosage Middle Aged Multiple myeloma Multiple Myeloma - complications Multiple Myeloma - genetics Multiple Myeloma - therapy Mutation Myeloablative Agonists - administration & dosage Platelet Count Public Health Stem cell transplantation Stem Cells Thrombocythemia Thrombocythemia, Essential - complications Thrombocythemia, Essential - genetics Thrombocythemia, Essential - therapy Thrombocytosis Transfusions. Complications. Transfusion reactions. Cell and gene therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!